Table 3.
Author | Type+ | Age++ | No. Assessed* | Pretransplant eGFR | 1 Year eGFR | Final eGFR | ΔeGFR | |
---|---|---|---|---|---|---|---|---|
|
||||||||
All Studies | Delgado^^28 | Allo | A | 241 | 103.0 | 51.2 | 31.3 | −71.7 |
Parikh36 | Allo | A | 26 | 106.0 | 52.0 | … | −54.0 | |
Weiss^^4 | Allo | A | 91 | 80.0 | 81.9 | … | 1.9 | |
Kist-van Holthe^^13 | Allo | P | 40 | 118.0 | 97.0 | 97.0 | −21.0 | |
Kist-van Holthe^^13 | Allo | P | 122 | 116.0 | 98.0 | 104.0 | −12.0 | |
Glynne39 | Auto | A | 58 | 111.0 | … | … | … | |
Lonnerholm21 | Auto | A | 50 | 94.0 | 85.0 | 82.0 | −12.0 | |
Frisk20 | Auto | P | 34 | 125.0 | … | 107.0 | −18.0 | |
Lonnerholm21 | Auto | P | 22 | 114.0 | 103.0 | 103.0 | −11.0 | |
Carlson37 | Auto | P/A | 19 | 92.7 | … | 58.0 | −34.7 | |
Miralbell^^35 | Both | A | 41 | 102.0 | 73.0 | 77.0 | −25.0 | |
LeBlond34 | Both | A | 60 | 107.0 | … | 92.0 | −15.0 | |
Patzer40 | Both | P/A | 41 | 130.0 | 123.0 | 105.0 | −25.0 | |
Hingorani^^30 | Both | P/A | 1635 | 100.0 | 79.6 | 79.6 | −20.4 | |
|
||||||||
Weighted Averages | 2480 | 101.9 | 78.7 | 77.4 | −24.5 | |||
|
||||||||
Allo Only | Delgado^^28 | Allo | A | 241 | 103.0 | 51.2 | 31.3 | −71.7 |
Parikh36 | Allo | A | 26 | 106.0 | 52.0 | … | −54.0 | |
Weiss^^4 | Allo | A | 91 | 80.0 | 81.9 | … | 1.9 | |
Kist-van Holthe^^13 | Allo | P | 40 | 118.0 | 97.0 | 97.0 | −21.0 | |
Kist-van Holthe^^13 | Allo | P | 122 | 116.0 | 98.0 | 104.0 | −12.0 | |
|
||||||||
Weighted Averages | 520 | 103.3 | 64.1 | 56.2 | −40.0 | |||
|
||||||||
Auto Only | Glynne39 | Auto | A | 58 | 111.0 | … | … | … |
Lonnerholm21 | Auto | A | 50 | 94.0 | 85.0 | 82.0 | −12.0 | |
Frisk20 | Auto | P | 34 | 125.0 | … | 107.0 | −18.0 | |
Lonnerholm21 | Auto | P | 22 | 114.0 | 103.0 | 103.0 | −11.0 | |
Carlson37 | Auto | P/A | 19 | 92.7 | … | 58.0 | −34.7 | |
|
||||||||
Weighted Averages | 183 | 107.4 | 90.5 | 88.8 | −18.6 | |||
|
||||||||
Allo Auto & | Miralbell^^35 | Both | A | 41 | 102.0 | 73.0 | 77.0 | −25.0 |
LeBlond34 | Both | A | 60 | 107.0 | … | 92.0 | −15.0 | |
Patzer40 | Both | P/A | 41 | 130.0 | 123.0 | 105.0 | −25.0 | |
Hingorani^^30 | Both | P/A | 1635 | 100.0 | 79.6 | 79.6 | −20.4 | |
|
||||||||
Weighted Averages | 1777 | 101.0 | 80.5 | 80.5 | −20.4 | |||
|
Estimated GFR data organized by type of HCT performed. Data is organized by recipient age. Weighted averages are included at the bottom of each table.
= Type of transplants performed in study: Allo = data from only allogeneic recipients; Auto = data from only autologous recipients; Both = data from both allogeneic and autologous transplant recipients.
= Age of transplant recipients: A = adults (greater than 18 years old); P = pediatrics (less than 18 years old); P/A: patients from all age groups included.
= number of patients who underwent HCT, survived greater than 100 days and had kidney function assessed.
= updated data came from personal communication with author of study; … = data not available; Δ = post transplant minus pre transplant measurement: Final eGFR was a measurement taken between 18 and 36 months after HCT.